Erivedge BCC Approval Buoys Hedgehog Fans, But Pathway Needs Proof In Other Cancers
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA approval of Curis/Genentech’s hedgehog inhibitor Erivedge validates the class, but basal cell carcinoma is only the ante; cancers exploit hedgehog signaling in a variety of ways yet to be elucidated.
You may also be interested in...
The Hype And Hope Of Cancer Stem Cell Therapeutics
A wave of recent deals demonstrates a growing belief in the potential cancer stem cells might offer for more effective cancer therapies. Some say there’s more hope and hype than science behind the activity. As the science unfolds, fundamental questions have yet to be answered about the pathway to products, especially as drug developers train their lines of sight on solid tumors.
Curis Set For Transformative Year With Erivedge Skin Cancer Approval
Approved nearly six weeks before the March 8 PDUFA date, Erivedge (vismodegib) will be available to treat advanced basal cell cancers in a week or two for about $7,500 a month wholesale, partner Genentech said.
Pfizer Touts Bosutinib Advantages, Debuts Hedgehog Inhibitor At ASH
Among its presentations at the American Society of Hematology meeting, Pfizer debuted Hedgehog Smoothen inhibitor PF-04449913, showing off encouraging Phase I monotherapy data in highly refractory patients. The drug would pair nicely with late-stage bosutinib to hit chronic myelogenous leukemia in two ways: through stem cells and through mature cells, Pfizer’s Rothenberg said.